Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Dose-Response Relationship, Drug
Everolimus
/ therapeutic use
Female
Humans
Indoles
/ administration & dosage
MTOR Inhibitors
/ pharmacology
Male
Maximum Tolerated Dose
Middle Aged
Neoplasms
/ drug therapy
Protein Kinase Inhibitors
/ pharmacology
Pyrroles
/ administration & dosage
Pyrrolidines
/ administration & dosage
Receptors, Colony-Stimulating Factor
/ drug effects
Receptors, Platelet-Derived Growth Factor
/ drug effects
Receptors, Vascular Endothelial Growth Factor
/ antagonists & inhibitors
Everolimus
Neuroendocrine carcinoma
Phase 1
Renal cell carcinoma
Vorolanib
X-82
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
11
12
2020
accepted:
23
02
2021
pubmed:
20
3
2021
medline:
3
2
2022
entrez:
19
3
2021
Statut:
ppublish
Résumé
Background Anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) combined with mTOR inhibitors, like everolimus, result in significant responses and prolonged progression-free survival (PFS) among patients with renal cell carcinoma (RCC) [1]. However, everolimus doses >5 mg are often not tolerated when combined with other TKIs
Identifiants
pubmed: 33738668
doi: 10.1007/s10637-021-01093-7
pii: 10.1007/s10637-021-01093-7
doi:
Substances chimiques
Indoles
0
MTOR Inhibitors
0
Protein Kinase Inhibitors
0
Pyrroles
0
Pyrrolidines
0
Receptors, Colony-Stimulating Factor
0
Everolimus
9HW64Q8G6G
Receptors, Platelet-Derived Growth Factor
EC 2.7.10.1
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
vorolanib
YP8G3I74EL
Banques de données
ClinicalTrials.gov
['NCT01784861']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1298-1305Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473–1482. https://doi.org/10.1016/S1470-2045(15)00290-9
doi: 10.1016/S1470-2045(15)00290-9
pubmed: 26482279
Cohen MM Jr (2009) Judah Folkman, MD, 1933-2008: father of angiogenesis. J Craniofac Surg 20(Suppl 1):590–591. https://doi.org/10.1097/SCS.0b013e3181927e8a
doi: 10.1097/SCS.0b013e3181927e8a
pubmed: 19293676
Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1(2):193–202
doi: 10.1016/S1535-6108(02)00031-4
Hansel DE, Rahman A, Hermans J, de Krijger RR, Ashfaq R, Yeo CJ, Cameron JL, Maitra A (2003) Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 16(7):652–659. https://doi.org/10.1097/01.MP.0000077416.68489.50
doi: 10.1097/01.MP.0000077416.68489.50
pubmed: 12861060
Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309. https://doi.org/10.1016/j.ccr.2005.09.005
doi: 10.1016/j.ccr.2005.09.005
pubmed: 16226705
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316–1323. https://doi.org/10.1200/JCO.2007.13.6374
doi: 10.1200/JCO.2007.13.6374
pubmed: 18323556
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422–5428. https://doi.org/10.1200/JCO.2008.16.9847
doi: 10.1200/JCO.2008.16.9847
pubmed: 18936475
pmcid: 2651074
Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150. https://doi.org/10.1200/JCO.2009.26.7849
doi: 10.1200/JCO.2009.26.7849
pubmed: 20368553
Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16(4):525–537. https://doi.org/10.1093/annonc/mdi113
doi: 10.1093/annonc/mdi113
pubmed: 15728109
Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168(6):960–976. https://doi.org/10.1016/j.cell.2017.02.004
doi: 10.1016/j.cell.2017.02.004
pubmed: 28283069
pmcid: 28283069
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. https://doi.org/10.1016/S0140-6736(08)61039-9
doi: 10.1016/S0140-6736(08)61039-9
pubmed: 18653228
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, Rad001 in Advanced Neuroendocrine Tumors TTSG (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (6):514–523. doi: https://doi.org/10.1056/NEJMoa1009290
Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Oberg K (2016) Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol 34(32):3906–3913. https://doi.org/10.1200/JCO.2016.68.0702
doi: 10.1200/JCO.2016.68.0702
pubmed: 27621394
pmcid: 5791842
Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, Harrow K, Liang C (2019) Phase I, first-in-human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Vorolanib in patients with advanced solid tumors. Oncologist 24(4):455–e121. https://doi.org/10.1634/theoncologist.2018-0740
doi: 10.1634/theoncologist.2018-0740
pubmed: 30478190
Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ (2012) Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118(7):1868–1876. https://doi.org/10.1002/cncr.26429
doi: 10.1002/cncr.26429
pubmed: 21898375
Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ (2014) A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 12(4):241–250. https://doi.org/10.1016/j.clgc.2013.11.020
doi: 10.1016/j.clgc.2013.11.020
pubmed: 24685058
Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C (2015) Multicenter phase II trial of Temsirolimus and Bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol 33(14):1551–1556. https://doi.org/10.1200/JCO.2014.56.2082
doi: 10.1200/JCO.2014.56.2082
pubmed: 25488966
Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS (2015) Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas 44(2):190–197. https://doi.org/10.1097/MPA.0000000000000255
doi: 10.1097/MPA.0000000000000255
pubmed: 25426617
pmcid: 6063309
Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J (2020) Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine 55:102755. https://doi.org/10.1016/j.ebiom.2020.102755
doi: 10.1016/j.ebiom.2020.102755
pubmed: 32335374
pmcid: 7184160